TipHub

356.9

+1 +0.28%

As of 27 Jul 2026 · delayed

NSE Listed

Gujarat Themis Biosyn Ltd. (GUJTHEM)

Volume: 33,813Avg Vol 1W: 44,515Avg Vol 1M: 77,979.8552W Range:225.05479
Key Ratios
Checked 2d ago
Market Cap₹3,966 Cr
Current Price₹356.9
Previous Close₹355.9
High / Low (52w)₹479 / ₹225.05
Volume33,813
Avg Vol (1W)44,515
Avg Vol (1M)77,979.85
Stock P/E362.45
Book Value₹26.4
Dividend Yield
ROE
ROA
Revenue (TTM)₹152 Cr
Revenue Growth
Profit Margin
Total Debt₹162 Cr
Shares Outstanding
Face Value₹1
EPS (TTM)₹1
P/B13.73
Debt / Equity
50 DMA₹386.16
200 DMA₹369.21
Day change+0.28%
Price Chart
356.9 8.43% · 1Y
47022796.6L
2025-07-29
2026-07-27

20-day avg volume: 78K shares

Cons
  • Stock trades at a high P/E of 362.
Quarterly Results
MetricJun 2024Sept 2024Dec 2024Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026
Revenue₹39 Cr₹35 Cr₹40 Cr₹38 Cr₹36 Cr₹42 Cr₹43 Cr₹44 Cr
EBITDA₹18 Cr₹14 Cr₹18 Cr₹16 Cr₹12 Cr₹19 Cr₹18 Cr₹16 Cr
Net Profit₹13 Cr₹11 Cr₹13 Cr₹12 Cr₹9 Cr₹14 Cr₹12 Cr₹11 Cr
EPS
Profit & Loss (Annual)
MetricMar 2018Mar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025
Revenue₹39 Cr₹43 Cr₹87 Cr₹94 Cr₹119 Cr₹155 Cr₹174 Cr₹152 Cr
EBITDA₹5 Cr₹8 Cr₹32 Cr₹42 Cr₹60 Cr₹78 Cr₹80 Cr₹66 Cr
Net Profit₹4 Cr₹6 Cr₹24 Cr₹30 Cr₹44 Cr₹58 Cr₹59 Cr₹49 Cr
EPS2.664.4116.320.7730.0339.940.724.48
Balance Sheet
MetricMar 2019Mar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Total Assets₹33 Cr₹64 Cr₹88 Cr₹123 Cr₹166 Cr₹221 Cr₹301 Cr₹503 Cr
Total Liabilities₹14 Cr₹22 Cr₹18 Cr₹19 Cr₹17 Cr₹20 Cr₹53 Cr₹216 Cr
Equity₹19 Cr₹42 Cr₹70 Cr₹103 Cr₹149 Cr₹201 Cr₹248 Cr₹288 Cr
Total Debt₹162 Cr
Cash Flow
MetricMar 2020Mar 2021Mar 2022Mar 2023Mar 2024Mar 2025Mar 2026
Operating₹8 Cr₹21 Cr₹55 Cr₹60 Cr₹84 Cr₹108 Cr₹49 Cr
Investing₹-3 Cr₹-2 Cr₹-30 Cr₹-20 Cr₹-55 Cr₹-112 Cr₹-172 Cr
Financing₹2 Cr₹-5 Cr₹-14 Cr₹-13 Cr₹-9 Cr₹26 Cr₹115 Cr
Free Cash Flow₹8 Cr₹21 Cr₹55 Cr₹60 Cr₹84 Cr₹108 Cr₹-124 Cr
Shareholding
Promoter 70.86% Institutions 2.94% Public 26.19%
About Gujarat Themis Biosyn Ltd.

Healthcare · Drug Manufacturers - Specialty & Generic

Gujarat Themis Biosyn Limited engages in the manufacture of pharmaceuticals and medicinal chemicals in India and Japan. The company offers bulk drugs on job work basis in India. Its products include Rifamycin-S, an intermediate for the treatment of tuberculosis, Mycobacterium avium complex, leprosy, and Legionnaires' disease; Rifamycin-O for the treatment of traveler's diarrhea, irritable bowel syndrome, and hepatic encephalopathy; and Lovastatin. The company was incorporated in 1981 and is based in Mumbai, India.

www.gtbl.in
Efficiency & Working Capital
ROCE14.5%
Interest Coverage183.1
Dividend Payout
Debtor Days76 d
Inventory Days12 d
Payable Days35 d
Cash Conversion Cycle52 d
Working Capital Days88 d
Shareholding Details

As of 2026-06-30

Promoter70.9%
FII1.8%
DII1.2%
Institutions2.9%
Public26.2%
Promoter Pledge68.5%
No. of Shareholders27,010
Shareholding Pattern

Quarterly — figures in %. Latest 12 quarters.

PeriodDec 2023Mar 2024Jun 2024Sept 2024Dec 2024Feb 2025Mar 2025Jun 2025Sept 2025Dec 2025Mar 2026Jun 2026
Promoters70.9%70.9%70.9%70.9%70.9%70.9%70.9%70.9%70.9%70.9%70.9%70.9%
FIIs0.9%1%1.4%1.5%1.4%1.5%1.9%2.5%3%2%1.8%1.8%
DIIs0%0.8%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%1.2%
Public28.2%27.3%26.5%26.5%26.5%26.5%26%25.5%25%26%26.2%26.2%
Promoter Pledge3.3%3.3%3.3%3.3%3.3%3.3%3.3%3.3%3.3%4.5%5.4%68.5%
No. of Shareholders28,65529,57630,28031,27130,93430,43630,67328,94528,31927,32526,88627,010
Returns History (ROE / ROCE / ROA)
PeriodROEROCEROAP/E
202503
Major Shareholders (>1%)
NameCategoryStakeShares
Pharmaceutical Business Group [india] LtdShareholding of Promoter and Promoter Group47%5.12 Cr
Themis Medicare LimitedShareholding of Promoter and Promoter Group20.9%2.28 Cr
Sachin Dinesh PatelShareholding of Promoter and Promoter Group2.3%24,97,200
Quant Mutual Fund - Quant Manufacturing FundPublic Shareholding1.2%12,54,000
Ayushmat LtdPublic Shareholding1.1%12,20,000
Dinesh Shantilal Patel, Jayshree Dinesh Patel, Sachin Dinesh Patel (trustees Of Vividhmargi Trust)Shareholding of Promoter and Promoter Group0.6%6,60,297
Anay Rupen ChoksiShareholding of Promoter and Promoter Group0%22,852
Nysha Rupen ChoksiShareholding of Promoter and Promoter Group0%22,852
Dinesh Shantilal PatelShareholding of Promoter and Promoter Group0%15
Jayshree D PatelShareholding of Promoter and Promoter Group0%10
Reena S PatelShareholding of Promoter and Promoter Group0%10
Oss Software Solutions Labs Private LimitedShareholding of Promoter and Promoter Group0%0
Promoter Pledges
HolderPledged Shares% of HoldingAs of
Pharmaceutical Business Group [india] Ltd25,50,0005%2026-06-30
Themis Medicare Limited16,50,0007.2%2026-06-30
Board of Directors
NameDesignationYear
Dinesh S PatelChairman & Non Executive Dir.2025
Sachin D PatelManaging Director2025
Kirandeep MadanIndependent Non Exe. Director2025
Hitesh Dharmasinh GajariaIndependent Non Exe. Director2025
K G AnanthakrishnanIndependent Non Exe. Director2025
NIHAR AJAY PARIKHIndependent Director2025
Rajneesh AnandAdditional Director2025
Segments — Product
SegmentRevenueShare
Bulk Drugs for its own & Job Work₹0 Cr
Segments — Geography
RegionRevenueShare
India₹151 Cr100%
Capital Structure (₹ Cr)
YearFace ValueAuthorisedIssuedPaid-up
2025₹1251111
Corporate Actions
TypeDateValueRemark
dividend2025-09-04₹0.67 (67%)Final
Related-Party Transactions (₹ Cr)
YearSubsidiariesAssociatesJVKMPOthersTotal
2025000213
2025000011
2025000202
Insider / Designated-Person Trades

7 recent disclosure(s)

Pharmaceutical Business Group [India] LtdDisposal · 30,00,000
Mrs.Avantika Vijay AgarwalAcquisition · 5,400
Mrs.Avantika Vijay AgarwalDisposal · 3,704
Ms. Avantika Vijay AgarwalDisposal · 656
Ms. Avantika Vijay AgarwalDisposal · 9,032
Pharmaceutical Business Group India LimitedAcquisition · 38,50,000
Substantial Acquisitions (SAST)

1 disclosure(s)

NULL30/06/2026 - 03/07/2026 · 26,00,000
Company Information
Incorporated1981
ChairmanDinesh S Patel
AuditorGMJ & Co
🌐 www.gtbl.in

📍 69/C GIDC Industrial Estate, Valsad Dist, VAPI, Gujarat, 396195

Technical AnalysisPremium

Technical analysis (Premium)

Log in to see RSI, MACD, moving averages, oscillators and pivot levels for this stock.

More stocks

Prices are delayed/indicative; pros & cons are AI generated. Informational only — not investment advice. ← Back to search